Archived News
In August 2021 Finfeed changed from a website that covered ASX listed news to a website
that covered a select range of ASX
listed small cap Biotech stocks that we are personally
invested in: find out more.
The old Finfeed website, and all of the old articles are kept here for record keeping purposes.
VISIT NEW SITEengage:BDR receives funding support from US government
1 minute read
engage:BDR (ASX: EN1; EN1O) has received approval for SBA EIDL funding under its application for the US CARES Act EIDL (economic injury disaster loan).
The initial funding for EN1 is US$150,000 or $230,000 which is the program’s current maximum.
Management expects additional legislation to be passed in the coming months, potentially resulting in an increase in the EIDL and PPP funds as the original cap on this program was US$2 million.
The terms for this funding include a 30-year payment term, 3.75% interest rate, monthly payments of $731 starting 12 months after closing and a US$100 filing fee.
The company clarified one aspect of the funding after receiving an inquiry regarding the potential for EN1 to return any SBA funding (PPP or EIDL) because it is a listed entity.
On this note, the key factor is that EN1 is a listed entity in Australia, not the US.
The entity which received funding, engage:BDR, LLC, is a private US corporation, with all of its full-time employees working within the US borders.
Management does not foresee any issues or potential for returning SBA funding.
There have been a small number of listed, multi-billion-dollar market cap companies in the US that have voluntarily returned their funding, but EN1 does not fit into this category.
Latest articles on engage:BDR Limited
More Commentary
FYI establishes ties with independent ESG reporting platform
01-07-2021
Australian Government Awards FYI National Project Status
29-06-2021
AHI and Nexus-Vita to fast track integration
22-06-2021
Oneview signs long-term contract with a second Victorian hospital
18-06-2021S3 Consortium Pty Ltd (CAR No.433913) is a corporate authorised representative of LeMessurier Securities Pty Ltd (AFSL No. 296877). The information contained in this article is general information only. Any advice is general advice only. Neither your personal objectives, financial situation nor needs have been taken into consideration. Accordingly you should consider how appropriate the advice (if any) is to those objectives, financial situation and needs, before acting on the advice.
Conflict of Interest Notice
S3 Consortium Pty Ltd does and seeks to do business with companies featured in its articles. As a result, investors should be aware that the Firm may have a conflict of interest that could affect the objectivity of this article. Investors should consider this article as only a single factor in making any investment decision. The publishers of this article also wish to disclose that they may hold this stock in their portfolios and that any decision to purchase this stock should be done so after the purchaser has made their own inquires as to the validity of any information in this article.
Publishers Notice
The information contained in this article is current at the finalised date. The information contained in this article is based on sources reasonably considered to be reliable by S3 Consortium Pty Ltd, and available in the public domain.